Skip to main content
SpringerLink
Log in

Mechanisms of Drug Action in Atrial Fibrillation

  • Chapter
Cardiac Arrhythmias, Pacing & Electrophysiology

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 201))

  • 178 Accesses

Abstract

Atrial fibrillation was first described electrocardiographically in 19091. Recently its important role as a cause of morbidity and mortality has become apparent. More than 3 million cases of atrial fibrillation are currently present in the United States2 and the number will increase further with the ageing of the population. The condition accounts for approximately 75 000 strokes per year in the United States3.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lewis T. Auricular fibrillation: a common clinical condition. Br Med J 1909; 2: 1528.

    Article  PubMed  CAS  Google Scholar 

  2. Waldo AL, Pratt CM. Acute treatment of atrial fibrillation and flutter-ibutilide in perspective. Am J Cardiol 1996; 78: 1–2.

    Article  PubMed  CAS  Google Scholar 

  3. Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973–7.

    Article  PubMed  CAS  Google Scholar 

  4. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke 1988; 19: 937–41.

    Article  PubMed  CAS  Google Scholar 

  5. Michelucci A, Padeletti L, Fradella GA. Atrial refractoriness and spontaneous or induced atrial fibrillation. Acta Cardiol 1982; 5: 333–44.

    Google Scholar 

  6. Cosio FG, Palacios J, Vidal JM, Cocina EG, Gomez-Sanchez MA, Tamargo L. Electrophysiologic studies in atrial fibrillation. Slow conduction of the background for reentry. Am J Cardiol 1983; 51: 122–30.

    Article  PubMed  CAS  Google Scholar 

  7. Henry WL, Morganroth J, Pearlman AS et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976; 53: 273–9.

    Article  PubMed  CAS  Google Scholar 

  8. Coumel P. Paroxysmal atrial fibrillation: a disorder of autonomic tone? Eur Heart J 1994; 15: 9–16.

    Article  PubMed  Google Scholar 

  9. Schwartz PJ, Zara A. The Sicilian Gambit revisited theory and practice. Eur Heart J 1992; 13 (suppl. F): 23–9.

    Article  PubMed  Google Scholar 

  10. Bigger TJ Jr, Breithardt G, Brown AM et al. The Task Force of the working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831–51.

    Article  Google Scholar 

  11. Spratt KA, Docherty JE. Digitalization: principles and practice of digitalis. In Messerli FH, editor. Cardiovascular Drug Therapy. Philadelphia, WB Saunders; 1996: 1136–46.

    Google Scholar 

  12. Wellens HJJ, Durrer D. Effect of digitalis on atrioventricular conduction and circus movement tachycardia in patients with Wolf-Parkinson-White syndrome. Circulation 1973; 47: 1229–33.

    Article  PubMed  CAS  Google Scholar 

  13. Falk RH. Proarrhythmic responses to atrial anti-arrhythmic therapy. In Falk RH, Podrid PJ, editors. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press; 1992: 283–306.

    Google Scholar 

  14. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med 1987; 106: 503–6.

    PubMed  CAS  Google Scholar 

  15. Kuppersmith J. Cellular mechanisms of antiarrhythmic action of beta blockers. In Deedwania PC, editor. Betablockers and Cardiac Arrhythmias. New York: Marcel Dekker; 1992: 1–30.

    Google Scholar 

  16. Anastasiou-Nana MI, Nanas JN, Menlove RL, Anderson JL. Experimental antifibrillatory effects of calcium channel blockade with diltiazem: comparison with 0-blockade and nitroglycerin. J Cardiovasc Pharmacol. 1984; 6: 780–7.

    Article  PubMed  CAS  Google Scholar 

  17. The Esmolol vs Placebo Multicenter Study Group: Anderson S, Blanski L, Byrd RC et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am Heart J 1986; 111: 42–8.

    Article  PubMed  CAS  Google Scholar 

  18. The Esmolol vs placebo Multicenter Study Group: Abrams J, Allen J, Allin D et al. Efficacy and safety of esmolol vs propranolol in the treatment of supra-ventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am Heart J 1985; 110: 913–22.

    Article  PubMed  CAS  Google Scholar 

  19. Singh BN, Control of cardiac arrhythmias by modulation of the slow myocardial channel. In Horowitz L, Partridge LD, Leach JK, editors. Calcium Channels, Their Properties, Functions, Regulation and Clinical Significance. Boca Raton, FL: CRC Press; 1991: 327–56.

    Google Scholar 

  20. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multi-center study. J Am Coll Cardiol 1991; 18: 891–9.

    Article  PubMed  CAS  Google Scholar 

  21. Roth A, Harrison E, Mitani G, Cohen J, Rahimtoola SH, Elkayam U. Efficacy and safety of medium-and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986; 73: 316–24.

    Article  PubMed  CAS  Google Scholar 

  22. Borgeat A, Goy J, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986; 58: 496–8.

    Article  PubMed  CAS  Google Scholar 

  23. Coplen SE, Antman E, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized controlled trials. Circulation 1990; 82: 1106–16.

    Article  PubMed  CAS  Google Scholar 

  24. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL on behalf of Stroke Prevention in Atrial Fibrillation Investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527–32.

    Article  PubMed  CAS  Google Scholar 

  25. Ogunkelu JB, Damato AN, Akhtar M et al. Electrophysiologic effects of procainamide in subtherapeutic to therapeutic doses in human atrioventricular conduction system. Am J Cardiol 1976; 37: 724–31.

    Article  PubMed  CAS  Google Scholar 

  26. Edvardsson N. Comparison of class I and class III action in atrial fibrillation. Eur Heart J 1993; 14 (suppl. H): 62–6.

    Article  PubMed  Google Scholar 

  27. Ladd AT. Procainamide induced lupus erythematosus. N Engl J Med 1962; 267: 1357–8.

    Article  PubMed  CAS  Google Scholar 

  28. Sharma AJ, Yee R, Graudon G, Klein GJ. Sensitivity and specificity of invasive and noninvasive testing for risk of sudden death in Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1987; 10: 373–81.

    Article  PubMed  CAS  Google Scholar 

  29. Campbell TJ, Morgan JJ. Treatment of atrial arrhythmias after cardiac surgery with intravenous disopyramide. Aust NZJ Med 1980; 10: 644–9.

    Article  CAS  Google Scholar 

  30. Stewart DE, Ikram H. The use of intravenous disopyramide for the conversion of supraventricular tachyarrhythmias. NZ Med J 1984; 97: 148–50.

    CAS  Google Scholar 

  31. Campbell TJ, Gavaghan TP, Morgan JJ. Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomized trial. Br Heart J 1985; 54: 86–90.

    Article  PubMed  CAS  Google Scholar 

  32. Teichman SL, Fisher JD, Matos JA, Kim SG. Disopyramide-pyridostignine: report of a beneficial drug interaction. J Cardiovasc Pharmacol 1985; 7: 108–13.

    Article  PubMed  CAS  Google Scholar 

  33. Wald RW, Waxman MB, Colman JM. Torsades de pointes ventricular tachycardia: a complication of diso- pyramide shared with quinidine. J Electrocardiol 1981; 14: 301–7.

    Article  PubMed  CAS  Google Scholar 

  34. Ikeda N, Singh BN, Davis LO, Hauswirth O. Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. J Am Coll Cardiol 1985; 5: 303–10.

    Article  PubMed  CAS  Google Scholar 

  35. Wang Z, Page P, Nattel S. Mechanism of flecainide’s antiarrhythmic action in experimental atrial fibrillation. Circ Res 1992; 71: 271–87.

    Article  PubMed  CAS  Google Scholar 

  36. Camm Ai, Katritsis D, Nuain SO. Effects of flecainide on atrial electrophysiology in Wolff-Parkinson-White syndrome. Am J Cardiol 1992; 70: 33–37A.

    Article  Google Scholar 

  37. Donovan KD, Cobb DJ, Coombs LJ et al. Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol 1991; 67: 137–41.

    Article  PubMed  CAS  Google Scholar 

  38. Madrid AH, Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in conversion of atrial fibrillation. Eur Heart J 1993; 14: 1127–31.

    Article  PubMed  CAS  Google Scholar 

  39. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo: the cardiac arrhythmia suppression trial. N Engl J Med 1991; 324: 781–8.

    Article  PubMed  CAS  Google Scholar 

  40. Anastasiou-Nana MI, Anderson JL, Stewart JR et al. Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable pro-arrhythmic effect. Am Heart J 1987; 113: 1071–7.

    Article  PubMed  CAS  Google Scholar 

  41. Kohlardt M, Seifert C. Inhibition of Vmax of the action potential by propafenone and its voltage-, time-and pH-dependence in mammalian ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 1980; 315: 55–62.

    Article  Google Scholar 

  42. Capucci A, Villani GQ, on behalf of the SATE Group. Propafenone oral dose plus digitalis in converting atrial fibrillation to sinus rhythm: a placebo-controlled trial. Circulation 1995; 92: 1–775 (abstract).

    Article  Google Scholar 

  43. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993; 88: 1063–71.

    Article  PubMed  CAS  Google Scholar 

  44. Anastasiou-Nana MI, Levis GM, Moulopoulos SD. Amiodarone: application and clinical pharmacology in atrial fibrillation and other arrhythmias. Int J Clin Pharmacol Ther Toxicol 1984; 22: 229–35.

    PubMed  CAS  Google Scholar 

  45. Brodsky MA, Allen BJ, Walker CJ, Casey TP, Luchett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60: 572–5.

    Article  PubMed  CAS  Google Scholar 

  46. Gosselink M, Crijins HJ, Van Gelder IC, Hilige H, Wiesfeld ACP, Lie KT. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. J Am Med Assoc 1992; 267: 3289–93.

    Article  CAS  Google Scholar 

  47. Zehender M, Hohnloser S, Muller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992; 19: 1054–9.

    Article  PubMed  CAS  Google Scholar 

  48. Anastasiou-Nana MI, Nanas JN, Nanas SN et al. Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study. J Am Coll Cardiol 1994; 23: 253–8.

    Article  PubMed  CAS  Google Scholar 

  49. Jung W, Manz M, Pizzulli L, Pfeiffer D, Luderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol. 1992; 70: 1023–7.

    Article  PubMed  CAS  Google Scholar 

  50. Anastasiou-Nana MI, Levis GM, Moulopoulos SD. Pharmacokinetics of amiodarone after intravenous and oral administration. J Clin Pharmacol Ther Toxicol. 1982; 20: 524–9.

    CAS  Google Scholar 

  51. Nanas JN, Anastasiou-Nana MI, Margari ZJ, Karli J, Moulopoulos SD. Redistribution of amiodarone in heart transplant recipients treated with the drug before operation. J Heart Lung Transplant. 1997; 16: 387–9

    PubMed  CAS  Google Scholar 

  52. Anastasiou-Nana MI, Anderson JL, Nanas JN et al. High incidence of clinical and subclinical toxicity associated with amiodarone treatment of refractory tachyarrhythmias. Can J Cardiol. 1986; 2: 138–45.

    PubMed  CAS  Google Scholar 

  53. Weinberg BA, Miles WM, Klein LS et al. Five year follow-up of 589 patients treated with amiodarone. Am Heart J 1993; 125: 109–20.

    Article  PubMed  CAS  Google Scholar 

  54. Singh BN. Electrophysiologic basis for the anti-arrhythmic actions of sotalol and comparison with other agents. Am J Cardiol 1993; 72: 8–18A.

    Article  Google Scholar 

  55. Sung RJ, Tan HL, Karagounis L et al and the Sotalol Multicenter Study Group. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J 1995; 129: 739–48.

    Article  PubMed  CAS  Google Scholar 

  56. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with dgoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol 1995; 76: 495–8.

    Article  PubMed  CAS  Google Scholar 

  57. Anastasiou-Nana MI, Anderson JL, Askins JC, Gilbert EM, Nanas JN, Menlove RL. Long-term experience with sotalol in the treatment of complex ventricular arrhythmias. Am Heart J 1987; 114: 288–96.

    Article  PubMed  CAS  Google Scholar 

  58. Anastasiou-Nana MI, Gilbert EM, Miller RH et al. Usefulness of d,1 sotalol for suppression of chronic ventricular arrhythmias. Am J Cardiol 1991; 67: 511–16.

    Article  PubMed  CAS  Google Scholar 

  59. Naccarelli GV, Lee KS, Gibson JK, VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996; 78 (suppl. 8A): 12–16.

    Article  PubMed  CAS  Google Scholar 

  60. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT and the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613–21.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Maria I. Anastasiou-Nana
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical School, University of Crete, Heraklion, Crete, Greece

    Panos E. Vardas (Professor of Cardiology) (Professor of Cardiology)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Anastasiou-Nana, M.I. (1998). Mechanisms of Drug Action in Atrial Fibrillation. In: Vardas, P.E. (eds) Cardiac Arrhythmias, Pacing & Electrophysiology. Developments in Cardiovascular Medicine, vol 201. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5254-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5254-9_4

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6210-7

  • Online ISBN: 978-94-011-5254-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation